← All indications
Salivary Gland Neoplasms
Tumors or cancer of the SALIVARY GLANDS.
Subtype terms (3)
More specific conditions that are subtypes of Salivary Gland Neoplasms in the MeSH hierarchy.
- Parotid Neoplasms
3 drugs (2 approved, 1 experimental)
- Sublingual Gland Neoplasms
- Submandibular Gland Neoplasms
Drugs by status
Phase 2 trials (62)
- 2-fluoropropionyl-labeled pegylated dimeric rgd peptide
- axitinib
- sorafenib
- darolutamide
- temsirolimus
- dovitinib
- doxorubicin
- eribulin
- entrectinib
- paclitaxel
- leuprolide
- goserelin
- lapatinib
- bicalutamide
- nivolumab
- ispinesib
- ixabepilone
- apalutamide
- pembrolizumab
- lenvatinib
- msk-2206
- opb-111001
- pazopanib
- pemetrexed
- buparlisib
- ipilimumab
- sunitinib
- rc48-adc
- alectinib
- sacituzumab govitecan
- +32 more
Phase 1 trials (25)
- fluorothymidine
- 7-hydroxystaurosporine
- alvespimycin
- irinotecan
- lenalidomide
- tacrolimus
- photochlor
- hydroxyurea
- motolimod
- methylene blue
- pv701
- fowlpox-sargramostim
- recombinant fowlpox-cea(6d)/tricom vaccine
- interleukin-12
- everolimus
- her-2 car-t cells
- sargramostim
- talactoferrin alpha
- fam-trastuzumab deruxtecan-nxki
- ceralasertib
- xmab20717
- psma car-t cell
- gq1001
- elimusertib
- ava6000
Other trials (5)
Organizations
Organization Involved with Phase 3 Indications (2)
Organization Involved with Phase 2 Indications (54)
- Eisai
- Bristol-Myers Squibb
- Amgen
- AstraZeneca
- Merck
- Genentech
- Sanofi-Synthelabo
- Ipsen
- Novartis
- Ascentage Pharma Group Inc.
- Ignyta, Inc.
- Otsuka
- University of Pennsylvania
- University of Pittsburgh
- Canadian Cancer Trials Group
- Cornell University
- Harvard University
- Eastern Cooperative Oncology Group
- Temple University
- University of Washington
- King Faisal University
- McMaster University
- NRG Oncology
- Northwestern University
- Ohio State University
- Oregon Health and Science University
- Radboud University
- Radiation Therapy Oncology Group
- Southwest Oncology Group
- Stanford University
- +24 more
Organization Involved with Phase 1 Indications (11)
- Agennix
- The EMMES Corporation
- AIDS Malignancy Consortium
- Baylor University
- Cancer and Leukemia Group B (CALGB)
- Hoosier Cancer Research Network
- Virginia Commonwealth University
- Vanderbilt University
- Methodist Cancer Center, Houston, Texas
- State University of New York, Buffalo
- Washington University in St. Louis
Organization Involved with Other Experimental Indications (1)